ClinicalTrials.gg
RecruitingNCT07042100Updated Jul 28, 2026

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

A Phase 1 interventional study of Dose level (DL)1 and DL2 in Advanced Solid Tumors, sponsored by Sun Pharma Advanced Research Company Limited. Recruiting at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Sun Pharma Advanced Research Company Limited (formerly part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
177
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

Read the detailed description

This study has two parts. In Part 1, the goal to evaluate the safety and tolerability along with the highest dose that can be tolerated, or the dose(s) which can be chosen for further evaluation. In Part 2, the focus is on evaluating the safety of SBO-154 in specific types of advanced cancers.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Sun Pharma Advanced Research Company Limited is the lead sponsor of 35 studies on the registry; 2 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give written and dated (or legally acceptable representative/ impartial witness when applicable) and is available for the entire study.
  2. Willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions (in the Investigator's opinion), and be accessible for follow-up.
  3. Has locally recurrent or disease (except sarcomas) which has or progressed following local standard treatment, or for which no standard treatment is available.
  4. Has a of ≥3 months.

Exclusion criteria

Exclusion Criteria:

  1. Any major surgery, as determined by the Investigator, within 4 weeks of SBO-154 administration.
  2. Evidence of organ dysfunction or any deviation from normal in physical examination.
  3. Known or suspected history of significant drug abuse as judged by the Investigator.
  4. Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals.
  5. Known or suspected history of excessive intake of alcohol in the 12 months prior to study entry.
  6. Positive exclusion tests: urine pregnancy tests (if applicable), serology tests positive for , , (unless they are considered subjects with resolved Hepatitis B and C infection).
  7. History of any relevant allergy/ including known immediate or delayed hypersensitivity reaction or idiosyncrasy to biological agents or drug chemically related to SBO-154 or its .
  8. Received an agent within 30 days or 5 half-lives- whichever is shorter prior to SBO-154 administration.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
177 participants (estimated)

Study arms

  • Experimental
    SBO-154

    Biological: Dose level (DL)1 · Biological: DL2 · Biological: DL3 · Biological: DL4 · Biological: DL5

Interventions

  • BiologicalDose level (DL)1

    Administered IV every 3 weeks

  • BiologicalDL2

    Administered IV every 3 weeks

  • BiologicalDL3

    Administered IV every 3 weeks

  • BiologicalDL4

    Administered IV every 3 weeks

  • BiologicalDL5

    Administered IV every 3 weeks

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities

    Applicable to Part 1 only

    Time frame: Twenty-one days from the initiation of the first dose of SBO-154 (3 weeks)

  2. Incidence of treatment-related serious adverse events

    Time frame: Throughout the study: from the start of study drug to 30 days post the last dose of study drug.

  3. Incidence of treatment-related adverse events

    Time frame: Throughout the study: from the start of study drug to 30 days post the last dose of study drug.

Secondary outcomes

  1. To evaluate the overall response rate (i.e., the percentage of participants who achieved a best response of Complete Response (CR) or Partial Response (PR), per RECIST v1.1)

    Time frame: Time Frame: Assessed every 6 weeks from the date of first study drug administration until the date of first documented disease progression, or death, whatever comes first; assessed for an average of 12 months.

  2. To evaluate the duration of response (i.e., the time from the initial response (CR or PR) to the time of progression of disease (PD) or death, per RECIST v1.1)

    Time frame: Time Frame: Assessed every 6 weeks from the date of first study drug administration until the date of first documented disease progression, or death, whatever comes first; assessed for an average of 12 months.

  3. To evaluate the disease control rate (i.e., the percentage of participants who achieved a best response of CR, PR, or remained stable disease (SD), per RECIST v1.1)

    Time frame: Time Frame: Assessed every 6 weeks from the date of first study drug administration until the date of first documented disease progression, or death, whatever comes first; assessed for an average of 12 months.

  4. To evaluate the time to response (i.e., the time from treatment start to the time-point where a best response of CR or PR was achieved, per RECIST v1.1)

    Time frame: Time Frame: Assessed every 6 weeks from the date of first study drug administration until the date of first documented disease progression, or death, whatever comes first; assessed for an average of 12 months.

  5. To evaluate the progression-free survival (i.e., the time from treatment start to the time of PD or death, per RECIST v1.1)

    Time frame: Time Frame: Assessed every 6 weeks from the date of first study drug administration until the date of first documented disease progression, or death, whatever comes first; assessed for an average of 12 months.

  6. Incidences of anti-drug antibodies (ADA)

    Time frame: Survival Follow-up: Upto 1 yr

  7. Incidences of titer antibodies

    Time frame: Survival Follow-up: Upto 1 yr

  8. Incidences of neutralizing antibodies

    Time frame: Survival Follow-up: Upto 1 yr

07

Study locations

12 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Aug 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 27, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2030
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07042100
Responsible party
Sponsor
First posted
Jun 27, 2025
Start date
Aug 12, 2025
Primary completion
Aug 2028 (estimated)
Completion
Aug 2030 (estimated)
Last update
Jul 28, 2026

Study contacts

Dr. Sandeep Inamdar
Contact
clinical.trials@sparcmail.com
91-22-66455645

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion